Matches in UGent Biblio for { <https://biblio.ugent.be/publication/4325294#aggregation> ?p ?o. }
Showing items 1 to 39 of
39
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B979797.
- aggregation creator B979798.
- aggregation creator B979799.
- aggregation creator B979800.
- aggregation creator B979801.
- aggregation creator B979802.
- aggregation creator B979803.
- aggregation creator B979804.
- aggregation creator B979805.
- aggregation creator B979806.
- aggregation creator person.
- aggregation date "2013".
- aggregation hasFormat 4325294.bibtex.
- aggregation hasFormat 4325294.csv.
- aggregation hasFormat 4325294.dc.
- aggregation hasFormat 4325294.didl.
- aggregation hasFormat 4325294.doc.
- aggregation hasFormat 4325294.json.
- aggregation hasFormat 4325294.mets.
- aggregation hasFormat 4325294.mods.
- aggregation hasFormat 4325294.rdf.
- aggregation hasFormat 4325294.ris.
- aggregation hasFormat 4325294.txt.
- aggregation hasFormat 4325294.xls.
- aggregation hasFormat 4325294.yaml.
- aggregation isPartOf urn:issn:0271-0749.
- aggregation language "eng".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale".
- aggregation abstract "The aim of this study was to develop a pharmacokinetic-pharmacodynamic (PKPD) model that quantifies the efficacy of haloperidol, accounting for the placebo effect, the variability in exposure-response, and the dropouts. Subsequently, the developed model was utilized to characterize an effective dosing strategy for using haloperidol as a comparator drug in future antipsychotic drug trials. The time course of plasma haloperidol concentrations from 122 subjects and the Positive and Negative Syndrome Scale (PANSS) scores from 473 subjects were used in this analysis. A nonlinear mixed-effects modeling approach was utilized to describe the time course of PK and PANSS scores. Bootstrapping and simulation-based methods were used for the model evaluation. A 2-compartment model adequately described the haloperidol PK profiles. The Weibull and E-max models were able to describe the time course of the placebo and the drug effects, respectively. An exponential model was used to account for dropouts. Joint modeling of the PKPD model with dropout model indicated that the probability of patients dropping out is associated with the observed high PANSS score. The model evaluation results confirmed that the precision and accuracy of parameter estimates are acceptable. Based on the PKPD analysis, the recommended oral dose of haloperidol to achieve a 30% reduction in PANSS score from baseline is 5.6 mg/d, and the corresponding steady-state effective plasma haloperidol exposure is 2.7 ng/mL. In conclusion, the developed model describes the time course of PANSS scores adequately, and a recommendation of haloperidol dose was derived for future antipsychotic drug trials.".
- aggregation authorList BK1375446.
- aggregation endPage "739".
- aggregation issue "6".
- aggregation startPage "731".
- aggregation volume "33".
- aggregation isDescribedBy 4325294.
- aggregation similarTo JCP.0b013e3182a4ee2c.
- aggregation similarTo LU-4325294.